A Pharmacokinetics Study to Assess Abiraterone Acetate Capsule and Tablet Formulations in Patients With Prostate Cancer

Inclusion Criteria: * Men with histologically, cytologically, or biochemically confirmed adenocarcinoma of the prostate * On-going androgen deprivation with serum testosterone \<50 ng/dL (\<2.0nmol/L) * Serum potassium \>=3.5 mmol/L * Eastern Cooperative Oncology Group (ECOG) Performance Status score \<2 (Karnofsky Performance Status \>=50%) * No history of adrenal insufficiency or hyperaldosteronism * Any acute toxicities of prior chemotherapy, radiotherapy have resolved to a NCI CTCAE (version 3.0) grade of \<=1 (chemotherapy induced alopecia and grade 2 neuropathy are excluded from this consideration) * No radiotherapy, chemotherapy, or immunotherapy within 30 days of administration of the study drug 1 (SD1) on Day 1 * No surgery or local prostatic intervention within 28 days of the first dose (any clinically relevant sequelae from the surgery must have resolved prior to SD1 on Day 1) * Agrees to protocol-defined use of effective contraception * Life expectancy \>12 weeks Exclusion Criteria: * Active or uncontrolled autoimmune disease that may require corticosteroid therapy * Serious or uncontrolled co-existent non-malignant disease, including active and uncontrolled infection * Uncontrolled hypertension * Protocol-defined laboratory values * Clinically significant heart disease as evidenced by a myocardial infarction in the past 12 months, severe or unstable angina, or New York Heart Association (NYHA) Class III or IV heart disease (patients with a history of atherosclerotic vascular disease requiring coronary or peripheral artery bypass surgery may be enrolled provided the surgery occurred at least 2 years prior to enrollment and after consultation with a cardiologist to insure that the disease is stable) * Other malignancy within the previous 5-years other than basal cell or squamous cell carcinomas of skin with a \>30% probability of recurrence within 12 months * History of gastrointestinal disorders (medical disorders or extensive surgery) which may interfere with the absorption of the study medication * Condition or situation which, in the investigator's opinion, may put the patient at significant risk, may confound the study results, or may interfere significantly with patient's participation in the study